In total , @ patients were randomized and @ received @ study medication dose ( all-treated ) , @ patients fulfilled inclusion/exclusion and continuation criteria ( all-treated target -LSB- ATT -RSB- ) ( telavancin @ , standard therapy @ ) , and @ patients were clinically evaluable ( CE ) ( telavancin @ , standard therapy @ ) .